)
Harvard Bioscience (HBIO) investor relations material
Harvard Bioscience Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
2025 marked a pivotal year with comprehensive refinancing, operational reorganization, and leadership enhancements, including the appointment of a new CEO and permanent CFO.
Manufacturing consolidation and governance improvements aimed at simplifying operations and supporting future growth.
Strategic focus shifted toward translational science, platform-based innovation, and recurring revenue streams.
Exited FY25 as a leaner, more efficient business with a strengthened balance sheet.
Net loss for 2025 was ($56.7M), primarily due to a $48M goodwill impairment.
Financial highlights
Q4 2025 revenue was $23.7M, above midpoint of guidance but down from $24.6M in Q4 2024; gross margin reached 59.77%, up 260 bps year-over-year.
Q4 adjusted EBITDA grew 27% year-over-year to $3.8M; operating income improved to $1.7M from flat last year.
Full year 2025 revenue was $86.6M, down from $94.1M, mainly due to tariffs and delayed NIH funding; adjusted EBITDA rose 12.5% to $8.1M.
GAAP net loss increased due to a $48M goodwill impairment; adjusted operating income and EPS were impacted by non-cash items.
Cash flow from operations improved to $6.7M from $1.4M in 2024.
Outlook and guidance
2026 guidance: revenue growth of 2%-4%, gross margin of 58%-60%, adjusted EBITDA growth of 6%-10%.
Q1 2026 expected revenue: $20M-$22M; adjusted gross margin: 57%-59%; adjusted EBITDA: $1M-$2.2M.
Revenue expected to ramp through 2026, driven by new product innovation and improved market conditions.
- Reverse stock split and adjournment proposals passed with over 97% approval.HBIO
EGM 20266 Mar 2026 - Q2 2024 revenue fell nearly 20% with net loss widening, prompting reduced full-year guidance.HBIO
Q2 20242 Feb 2026 - Growth driven by new organoid and bioproduction systems, with APAC recovery boosting outlook.HBIO
Jefferies Global Healthcare Conference1 Feb 2026 - Shareholders to vote on a reverse stock split to maintain Nasdaq listing and flexibility.HBIO
Proxy Filing30 Jan 2026 - Up to 9.5 million shares registered for resale, with no direct proceeds to the company.HBIO
Registration Filing30 Jan 2026 - Approval sought for a reverse stock split to maintain Nasdaq listing and shareholder value.HBIO
Proxy Filing20 Jan 2026 - New product launches and bioproduction expansion set the stage for double-digit growth.HBIO
Sidoti September Small-Cap Virtual Conference20 Jan 2026 - Revenue and margins declined, but cost cuts and new products support cautious Q4 optimism.HBIO
Q3 202416 Jan 2026 - Organoid and bioproduction innovations drive double-digit growth and recurring revenues.HBIO
Sidoti Micro-Cap Virtual Conference9 Jan 2026
Next Harvard Bioscience earnings date
Next Harvard Bioscience earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)